Compare Amgen, Inc. (AMGN) vs Shell PLC (SHEL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Shell PLC — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Shell PLC trades at $82.3 (market cap $222.30B). The key difference: Amgen, Inc. and Shell PLC are close in size by market cap, and Shell PLC pays the higher dividend (3.8%). Which is the better fit depends on your goals.
| AMGN | SHEL | |
|---|---|---|
Market Cap | $196.12B | $222.30B |
Sector | Health | Energy |
52-Week High | $388.16 | $94.15 |
52-Week Low | $271.18 | $70.28 |
Enterprise Value | $241.41B | $274.83B |
Dividend Yield | 2.77% | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
SHEL trades at $82.23, up 1.02% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 12.81 and net income margin of 7.01%. Recent Q1 2026 earnings beat expectations, and the company raised its Q2 outlook despite Middle East production disruptions. Analyst consensus is strongly bullish with a $122.20 price target.
The outlook for SHEL is positive, supported by elevated energy prices and strong gas trading, though geopolitical risks and declining operating cash flow pose headwinds. The stock offers value with attractive valuation multiples and a solid dividend, but investors should monitor production volatility and macroeconomic pressures on energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
